<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; LMNX</title>
	<atom:link href="http://www.stockbloghub.com/tag/lmnx/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(LMNX) Luminex Wraps Up EraGen Buy</title>
		<link>http://www.stockbloghub.com/2011/06/29/lmnx-luminex-wraps-up-eragen-buy/77787</link>
		<comments>http://www.stockbloghub.com/2011/06/29/lmnx-luminex-wraps-up-eragen-buy/77787#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:33:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77787</guid>
		<description><![CDATA[Luminex Corporation (LMNX), a developer of biological testing technologies, has completed its previously-announced acquisition of privately-held diagnostic testing company EraGen Biosciences, Inc. for $34 million in cash. The companies struck a definitive agreement on June 21. Madison, Wisconsin-based EraGen, with annual sales of $8 million, makes molecular reagent products for infectious diseases and genetic-based conditions. The company’s products are based on its proprietary MultiCode technology platform. The acquisition provides Luminex a highly complementary portfolio of molecular diagnostic tests based on the MultiCode platform. Besides, it enables the company to tap new markets leveraging EraGen’s innovative technologies. Luminex envisions the acquisition to add between $5 million and $7 million to its sales for 2011. Moreover, the company expects the transaction to dilute its earnings (on a reported basis) in 2011 and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/lmnx-luminex-wraps-up-eragen-buy/77787/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex MAGPIX Earns Stevie Award for Business</title>
		<link>http://www.stockbloghub.com/2011/06/26/lmnx-luminex-magpix-earns-stevie-award-for-business/77472</link>
		<comments>http://www.stockbloghub.com/2011/06/26/lmnx-luminex-magpix-earns-stevie-award-for-business/77472#comments</comments>
		<pubDate>Sun, 26 Jun 2011 17:26:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Cisco Systems]]></category>
		<category><![CDATA[CSCO]]></category>
		<category><![CDATA[DELL]]></category>
		<category><![CDATA[Dell Inc.]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[Hewlett-Packard Company]]></category>
		<category><![CDATA[HPQ]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77472</guid>
		<description><![CDATA[Luminex Corporation (LMNX), a developer of biological testing technologies, has clinched two American Business Awards (“Stevie Awards”) for its flagship MAGPIX analytical instrument. The Stevie Awards were created to honor organizations of all types and sizes and business people in recognition of their positive contributions and achievements in the workplace globally. The Texas-based company was crowned the “Most Innovative Company of the Year (for companies with less than 2,500 employees)” and “Business Innovation of the Year” awards for its innovative MAGPIX instrument. The awards were presented at a gala event at the New York Marriott Marquis Hotel in Times Square. Apart from Luminex, other notable winners of the Stevie Award include Apple Inc. (AAPL), Whole Foods Market Inc. (WFM), Cisco Systems Inc. (CSCO), Dell Inc (DELL), General Electric (GE) and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/26/lmnx-luminex-magpix-earns-stevie-award-for-business/77472/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Gets EraGen for $34M</title>
		<link>http://www.stockbloghub.com/2011/06/22/lmnx-luminex-gets-eragen-for-34m/77193</link>
		<comments>http://www.stockbloghub.com/2011/06/22/lmnx-luminex-gets-eragen-for-34m/77193#comments</comments>
		<pubDate>Thu, 23 Jun 2011 01:02:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77193</guid>
		<description><![CDATA[Luminex Corporation (LMNX), a developer of biological testing technologies, has forged a definitive agreement to buy Madison, Wisconsin-based privately-held diagnostic testing company EraGen Biosciences, Inc. for $34 million in cash. The transaction, which is subject to the clearance of EraGen shareholders and other customary conditions, is expected to complete within the next few weeks. EraGen, with annual sales of $8 million, makes molecular reagent products for infectious diseases and genetic-based conditions. The company’s products are based on its proprietary MultiCode technology platform. EraGen received, in May 2010, the approval of the U.S. Food and Drug Administration (“FDA”) for its MultiCode-RTx HSV 1&#38;2 Kit. It is the first FDA-approved molecular test for the herpes simplex virus (“HSV”). The acquisition will provide Luminex a highly complementary portfolio of molecular diagnostic tests based ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/lmnx-luminex-gets-eragen-for-34m/77193/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LIFE) Life Technologies Deals with Luminex</title>
		<link>http://www.stockbloghub.com/2011/06/14/life-life-technologies-deals-with-luminex/75397</link>
		<comments>http://www.stockbloghub.com/2011/06/14/life-life-technologies-deals-with-luminex/75397#comments</comments>
		<pubDate>Tue, 14 Jun 2011 18:56:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75397</guid>
		<description><![CDATA[Life Technologies Corporation (LIFE) recently entered into a global sales and distribution agreement with Luminex Corporation (LMNX) to access the latter’s award-winning multiplexing instrument MAGPIX to analyze proteins for research. This partnership is expected to be beneficial for MAGPIX as Life caters to scientists and researchers worldwide. On the other hand, Life expects MAGPIX to expand its cutting-edge antibody content across a broad range of protein quantitation needed in basic and clinical research. MAGPIX (launched in July 2010) is a compact, multiplex analyzer that helps efficient detection of 50 different analytes on a single sample, including proteins and nucleic acids. This product received the Medical Design Excellence Award in 2011 for its innovative design and contribution and recently received CE IVD mark in Europe. Life earns revenues from three divisions ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/life-life-technologies-deals-with-luminex/75397/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Tops Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2011/05/11/lmnx-luminex-tops-earnings-estimates/73741</link>
		<comments>http://www.stockbloghub.com/2011/05/11/lmnx-luminex-tops-earnings-estimates/73741#comments</comments>
		<pubDate>Thu, 12 May 2011 00:51:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73741</guid>
		<description><![CDATA[Luminex Corporation (LMNX), a developer of biological testing technologies, posted first-quarter fiscal 2011 earnings per share of 11 cents, comfortably beating the Zacks Consensus Estimate of 6 cents and exceeding the year-ago earnings of 5 cents. Profit more than doubled year over year to roughly $4.5 million owing to higher sales. Revenues shot up 30% year over year to $43.3 million, ahead of the Zacks Consensus Estimate of $40 million. The growth was led by solid consumables and assay sales. Consumable sales rocketed 53% to a record $15 million, buoyed by healthy demand from the company’s major partners. System revenues climbed 15% to $7.7 million, helped by healthy shipments of multiplexing analyzers. The Texas-based company shipped 197 analyzers (including 38 MAGPIX systems) in the quarter, flat year over year. Royalty ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/11/lmnx-luminex-tops-earnings-estimates/73741/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex MAGPIX Wins MDEA</title>
		<link>http://www.stockbloghub.com/2011/04/13/lmnx-luminex-magpix-wins-mdea/71348</link>
		<comments>http://www.stockbloghub.com/2011/04/13/lmnx-luminex-magpix-wins-mdea/71348#comments</comments>
		<pubDate>Wed, 13 Apr 2011 17:12:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71348</guid>
		<description><![CDATA[Luminex Corporation (LMNX), a developer of biological testing technologies, recently received the prestigious Medical Design Excellence Award (“MDEA”) for its MAGPIX analytical instrument. MDEA, organized by the leading business-to-business media company UBM Canon, is a premier awards program which recognizes the achievements of medical devices manufacturers. MAGPIX was recognized in the “In Vitro Diagnostics” category of the award, through a comprehensive review by a multi-disciplinary jury panel, for its innovative design and contribution. The award will be presented at a ceremony on June 8, 2011, at the Jacob K. Javits Convention Center in New York City. The MAGPIX system (launched in July 2010) leverages Luminex’s proprietary open-architecture xMAP technology and is capable of producing up to 50 tests on a single sample. The versatile multiplexing platform can be used to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/lmnx-luminex-magpix-wins-mdea/71348/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Corporation &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2011/02/10/lmnx-luminex-corporation-bear-of-the-day-2/66701</link>
		<comments>http://www.stockbloghub.com/2011/02/10/lmnx-luminex-corporation-bear-of-the-day-2/66701#comments</comments>
		<pubDate>Thu, 10 Feb 2011 17:52:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=66701</guid>
		<description><![CDATA[We reiterate our Underperform recommendation on Luminex Corp. (LMNX). Earnings for fourth quarter and fiscal 2010 beat the Zacks Consensus Estimates, but profit plummeted year-over-year despite an increase in revenues. Luminex operates in the highly competitive life sciences industry, which is characterized by rapid and continuous technological innovation. If Luminex is unable to respond to the changing requirements then its survival in the industry will be in question. Moreover, demand for research and diagnostics applications is expected to remain weak given the lingering economic softness, thereby affecting the company&#8217;s top line. Our $18 price target is based on 62.1x our fiscal 2011 earnings estimate. LUMINEX CORP (LMNX): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/10/lmnx-luminex-corporation-bear-of-the-day-2/66701/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Earns FDA Approval for New Diagnostic Test</title>
		<link>http://www.stockbloghub.com/2010/11/18/lmnx-luminex-earns-fda-approval-for-new-diagnostic-test/59911</link>
		<comments>http://www.stockbloghub.com/2010/11/18/lmnx-luminex-earns-fda-approval-for-new-diagnostic-test/59911#comments</comments>
		<pubDate>Thu, 18 Nov 2010 19:00:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[China Petroleum & Chemical Corporation]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SNP]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59911</guid>
		<description><![CDATA[Luminex Corporation (LMNX), a developer of biological testing technologies, has commenced the commercial launch of its first pharmacogenetic test following its recent approval by the U.S. Food and Drug Administration (FDA). Pharmacogenetics is the study of genetic factors that influence an individual&#8217;s response to drugs. The test, dubbed the xTAG CYP2D6 Kit, has been designed to bring in the personalized medicine approach by helping physicians to identify and manage patients for whom they may prescribe therapies which are metabolized by the cytochrome P450 2D6 (CYP2D6) enzyme. The xTAG CYP2D6 Kit will be marketed throughout the U.S. through Luminex Molecular Diagnostics (“LMD”), a unit of the company’s Assay segment. The CYP2D6 enzyme is involved in the metabolism of many prescription drugs. A segment of the population may carry a slow-acting or ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/18/lmnx-luminex-earns-fda-approval-for-new-diagnostic-test/59911/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Analyst Downgrades Shares to Underperform</title>
		<link>http://www.stockbloghub.com/2010/11/15/lmnx-luminex-analyst-downgrades-shares-to-underperform/59442</link>
		<comments>http://www.stockbloghub.com/2010/11/15/lmnx-luminex-analyst-downgrades-shares-to-underperform/59442#comments</comments>
		<pubDate>Tue, 16 Nov 2010 04:50:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59442</guid>
		<description><![CDATA[We downgrade our recommendation on Luminex Corporation (LMNX) to Underperform following the company’s lower-than-expected third quarter results and a less favorable outlook. Third-quarter fiscal 2010 adjusted loss per share of 2 cents missed the Zacks Consensus Estimate of earnings of 4 cents. Losses swelled 19% year over year as revenue growth was offset by higher costs and tax. Top line improved on solid consumables and assay sales, but missed the Zacks Consensus Estimate. Annualized decline in the shipments of analytical instruments contributed to lower system sales in the quarter.The company has narrowed its revenue forecast for fiscal 2010. Luminex develops, manufactures and markets proprietary biological testing technologies, which have applications across the life sciences industry. The company’s proprietary open-architecture xMAP technology enables fast, cost-effective and accurate conduct and analysis of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/lmnx-luminex-analyst-downgrades-shares-to-underperform/59442/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Analyst Maintains Neutral Rating</title>
		<link>http://www.stockbloghub.com/2010/04/09/lmnx-luminex-analyst-maintains-neutral-rating/33334</link>
		<comments>http://www.stockbloghub.com/2010/04/09/lmnx-luminex-analyst-maintains-neutral-rating/33334#comments</comments>
		<pubDate>Fri, 09 Apr 2010 21:48:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[NOC]]></category>
		<category><![CDATA[Northrop Grumman Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33334</guid>
		<description><![CDATA[We maintain our Neutral recommendation on Luminex Corp. (LMNX) with a target price of $18. Luminex boasts of a broad product portfolio. The company’s instrument base consists of the Luminex 100 (LX100), Luminex 200 (LX200) and FlexMap 3D systems. The Luminex 100 and 200 are compact analyzers that integrate fluidics, optics and digital signal processing to perform up to 100 bioassays simultaneously in a single tube or well of a microtiter plate using only a small amount of sample. In March 2010, Luminex and Northrop Grumman Corp. (NOC) agreed to create next generation autonomous biodetectors for monitoring the environment and alerting authorities regarding the release of potentially harmful airborne agents. We believe that the broad product portfolio will drive growth in the coming quarters. The company’s significant international presence is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/09/lmnx-luminex-analyst-maintains-neutral-rating/33334/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Corporation&#8217;s Revenues Expand</title>
		<link>http://www.stockbloghub.com/2010/02/08/lmnx-luminex-corporations-revenues-expand/27381</link>
		<comments>http://www.stockbloghub.com/2010/02/08/lmnx-luminex-corporations-revenues-expand/27381#comments</comments>
		<pubDate>Tue, 09 Feb 2010 03:48:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27381</guid>
		<description><![CDATA[Luminex Corp. (LMNX) reported fourth-quarter fiscal 2009 earnings (excluding the release of the valuation allowance) of $5.2 million or 12 cents per share, up from $2 million or 5 cents per share in the year-ago quarter. The Zacks Consensus Estimate for the reported quarter was a gain of 7 cents. Quarter in Detail Total revenues for the reported quarter came in at $38.2 million as against $28.2 million in the year-ago period, up approximately 35%. As per segments, revenues from the Technology segment came in at $24.8 million as against $22 million in the year-ago quarter. Assay group sales for the quarter came in at approximately $13.4 million, as against approximately $6.1 million in the comparable quarter of 2008. The company shipped 253 systems in the quarter. Cumulative systems shipments ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/08/lmnx-luminex-corporations-revenues-expand/27381/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Corporation Upgraded to Neutral</title>
		<link>http://www.stockbloghub.com/2010/01/18/lmnx-luminex-corporation-upgraded-to-neutral/25199</link>
		<comments>http://www.stockbloghub.com/2010/01/18/lmnx-luminex-corporation-upgraded-to-neutral/25199#comments</comments>
		<pubDate>Tue, 19 Jan 2010 00:15:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25199</guid>
		<description><![CDATA[Recently, we upgraded Luminex Corp. (LMNX) to Neutral from Underperform. Our decision to upgrade the stock was based on the company’s wide range of products and its significant international presence. These positive factors should drive growth in the coming quarters. Additionally, Luminex has an interesting pipeline. Should the pipeline develop successfully, the company can look at further growth. We are pleased with the company&#8217;s broad product portfolio. Luminex’s instrument base consists of the Luminex 100 (LX100), Luminex 200 (LX200) and FlexMap 3D systems. The Luminex 100 and 200 are compact analyzers that integrate fluidics, optics and digital signal processing to perform up to 100 bioassays simultaneously in a single tube or well of a microtiter plate using only a small amount of sample. By combining small diode lasers with digital ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/18/lmnx-luminex-corporation-upgraded-to-neutral/25199/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(UNH) Healthcare Stock Review &#8211; December 2009 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/12/17/unh-healthcare-stock-review-dec-2009-industry-outlook/23150</link>
		<comments>http://www.stockbloghub.com/2009/12/17/unh-healthcare-stock-review-dec-2009-industry-outlook/23150#comments</comments>
		<pubDate>Fri, 18 Dec 2009 00:58:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Health Care Plans]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BIOS]]></category>
		<category><![CDATA[BioScrip Inc.]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CI]]></category>
		<category><![CDATA[CIGNA Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>
		<category><![CDATA[HUM]]></category>
		<category><![CDATA[Humana Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MOH]]></category>
		<category><![CDATA[Molina Healthcare Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Polypore International Inc]]></category>
		<category><![CDATA[PPO]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23150</guid>
		<description><![CDATA[OVERVIEW The healthcare sector comprises different industries, ranging from managed care organizations, healthcare facilities providers and medical devices manufacturers to biotech and pharmaceutical companies. Consequently, we believe that investors in this sector should be mindful of the different drivers and appropriate metrics associated with the various sub-sectors. In the present scenario, investor sentiment in healthcare continues to be driven by decisions in Congress related to government funding and the state of the broader economy. In view of the ongoing healthcare reform debate in Congress, healthcare policy changes remain an important indicator to investing in the sector. Even though legislation &#8212; which aims to cover nearly all Americans by providing government subsidies to help pay premiums irrespective of health or income &#8212; was passed in the House of Representatives, it is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/17/unh-healthcare-stock-review-dec-2009-industry-outlook/23150/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Corporation &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2009/12/03/lmnx-luminex-corporation-bear-of-the-day/21822</link>
		<comments>http://www.stockbloghub.com/2009/12/03/lmnx-luminex-corporation-bear-of-the-day/21822#comments</comments>
		<pubDate>Thu, 03 Dec 2009 23:12:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21822</guid>
		<description><![CDATA[Luminex Corporation (LMNX) reported a third-quarter loss of $0.6 million or a penny per share as opposed to a net income of $3.2 million or 8 cents per share in the comparable period of 2008. The Zacks Consensus Estimate for the reported quarter was for a gain of 7 cents. The loss in the quarter was attributable to higher operating expenses. We remain concerned about the company&#8217;s dependence on partners for generating revenues, as the strategy has inherent risks. Furthermore, the competitive life sciences industry is characterized by rapid and continuous technological innovation which further challenges Luminex. The company&#8217;s strategy to grow by acquisitions is also risky. In view of these concerns, we downgrade the stock to Underperform. Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/03/lmnx-luminex-corporation-bear-of-the-day/21822/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Corporation Posts Loss</title>
		<link>http://www.stockbloghub.com/2009/11/30/lmnx-luminex-corporation-posts-loss/21552</link>
		<comments>http://www.stockbloghub.com/2009/11/30/lmnx-luminex-corporation-posts-loss/21552#comments</comments>
		<pubDate>Tue, 01 Dec 2009 00:36:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21552</guid>
		<description><![CDATA[Luminex Corporation (LMNX) reported a third-quarter loss of $0.6 million or 1 cent per share as opposed to a net income of $3.2 million or 8 cents in the comparable period of 2008. The Zacks Consensus Estimate for the reported quarter was a gain of 7 cents. The loss in the quarter was attributable to the higher operating expenses which more than offset the increase in revenues. Total revenues for the reported quarter came in at $29.1 million as against $28.9 million in the year-ago period, up 1%. As per segments, revenues from the Technology segment came in at 22 million as against $22.6 million in the year-ago quarter. Assay group sales for the quarter came in at approximately $7.1 million, up 12% over the comparable quarter of 2008. Total ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/30/lmnx-luminex-corporation-posts-loss/21552/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Corp &#8211; next-year estimate pegged at a whopping 359% earnings growth projection</title>
		<link>http://www.stockbloghub.com/2008/12/18/luminex-corp-next-year-estimate-pegged-at-a-whopping-359-earnings-growth-projection/1780</link>
		<comments>http://www.stockbloghub.com/2008/12/18/luminex-corp-next-year-estimate-pegged-at-a-whopping-359-earnings-growth-projection/1780#comments</comments>
		<pubDate>Thu, 18 Dec 2008 22:33:19 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=1780</guid>
		<description><![CDATA[Luminex Corp. (LMNX) is fresh off the heels of a great quarter in which the company swung into profitability from last year. The next-year estimate is extremely bullish and the company&#8217;s share price is rallying. Company Description Luminex Corp develops and manufactures proprietary biological testing technologies and products for the life sciences industry. The company has a market cap of $886 million. Third-Quarter Results Shares of LMNX have been rallying since the company reported strong third-quarter results on Nov 7. Revenue jumped to $29 million from $19.3 million last year. Income increased to $3.2 million from a loss of $1.9 million. This produced earnings of 8 cents per share, far ahead of analyst estimates of 1 cent. Luminex said that its results benefited from partnerships with Genzyme Corp. and Becton, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/12/18/luminex-corp-next-year-estimate-pegged-at-a-whopping-359-earnings-growth-projection/1780/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

